It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Humoral response to SARS-CoV-2 has been studied, predominantly the classical IgG and its subclasses. Although IgE antibodies are typically specific to allergens or parasites, a few reports describe their production in response to SARS-CoV-2 and other viruses. Here, we investigated IgE specific to receptor binding domain (RBD) of SARS-CoV-2 in a Brazilian cohort following natural infection and vaccination. Samples from 59 volunteers were assessed after infection (COVID-19), primary immunization with vectored (ChAdOx1) or inactivated (CoronaVac) vaccines, and booster immunization with mRNA (BNT162b2) vaccine. Natural COVID-19 induced IgE, but vaccination increased its levels. Subjects vaccinated with two doses of ChAdOx1 exhibited a more robust response than those immunized with two doses of CoronaVac; however, after boosting with BNT162b2, all groups presented similar IgE levels. IgE showed intermediate-to-high avidity, especially after the booster vaccine. We also found IgG4 antibodies, mainly after the booster, and they moderately correlated with IgE. ELISA results were confirmed by control assays, using IgG depletion by protein G and lack of reactivity with heterologous antigen. In our cohort, no clinical data could be associated with the IgE response. We advocate for further research on IgE and its role in viral immunity, extending beyond allergies and parasitic infections.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Adolfo Lutz Institute, Immunology Center, São Paulo, Brazil (GRID:grid.417672.1) (ISNI:0000 0004 0620 4215); University of São Paulo, Post Graduate Program Interunits in Biotechnology, São Paulo, Brazil (GRID:grid.11899.38) (ISNI:0000 0004 1937 0722)
2 Adolfo Lutz Institute, Virology Center, São Paulo, Brazil (GRID:grid.417672.1) (ISNI:0000 0004 0620 4215); Disease Control Coordination, Post Graduate Program in Public Health Surveillance, São Paulo, Brazil (GRID:grid.417672.1)
3 Adolfo Lutz Institute, Immunology Center, São Paulo, Brazil (GRID:grid.417672.1) (ISNI:0000 0004 0620 4215)
4 Santo André Healthy Secretary, Santo André, Brazil (GRID:grid.417672.1)
5 Adolfo Lutz Institute, Santo André Regional Center, Santo André, Brazil (GRID:grid.417672.1) (ISNI:0000 0004 0620 4215)
6 Santo André Healthy Secretary, Santo André, Brazil (GRID:grid.11899.38)